Benzinga | Apr 16, 2021 08:32AM EDT

Horizon Therapeutics To Present New Long-Term Data For UPLIZNA At American Academy of Neurology's 73rd Annual Meeting Apr. 17-22

Horizon Therapeutics plc (NASDAQ:HZNP) today announced new UPLIZNA (inebilizumab-cdon) data being presented at the American Academy of Neurology's 73rd Annual Meeting being held virtually April 17-22, 2021 (AAN 2021), including new, end-of-study data from the open-label extension period of the pivotal N-MOmentum trial in patients with NMOSD. UPLIZNA is the first and only FDA-approved anti-CD19 B-cell depleting humanized monoclonal antibody for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive NMOSD.